Differential efficacy of Conbercept vs. Ranibizumab on retinal microstructural changes in macular edema secondary to retinal vein occlusion during the loading phase.

Authors

Haiyue Yu, Zhijian Yao, Juan Teng, Qin Zhang, Tiangang Liu, Guang Zhu

Published in

Frontiers in medicine. Volume 13. Pages 1885798. Epub Aug 12, 2026.

Abstract

To compare the efficacy of Conbercept vs.Ranibizumab on retinal microstructural changes in patients with retinal vein occlusion-associated macular edema (RVO-ME) by evaluating multidimensional OCT biomarkers during the loading phase.
This retrospective cohort study analyzed treatment-naive RVO-ME patients receiving three monthly intravitreal injections of Conbercept or Ranibizumab. Propensity score matching (PSM) was used to balance baseline characteristics. Inter-group and intra-group comparisons of OCT biomarkers including central macular thickness (CMT), disorganization of the retinal inner layers ([DRIL), hyperreflective dots (HRD), intraretinal fluid (IRF), subretinal fluid (SRF), and ellipsoid zone (EZ) disruption] were performed using the Mann-Whitney U-test and the Friedman test. Generalized estimating equation (GEE) models were employed to evaluate longitudinal trends in CMT, DRIL, and IRF.
After PSM, 108 patients (54 per group) were analyzed. Both agents showed significant improvements in all OCT biomarkers and BCVA at months 1 and 3 compared to baseline (all P < 0.05). Inter-group comparisons revealed that Ranibizumab achieved significantly lower CMT at months 1 (P = 0.011) and 3 (P = 0.006), and lower IRF at month 1 (P = 0.008). Conversely, Conbercept demonstrated significantly lower DRIL at month 3 (P = 0.004). GEE analysis confirmed a significant treatment-time interaction for DRIL (P = 0.004), indicating a more favorable longitudinal recovery of inner retinal microstructure with Conbercept, whereas no significant differences were observed in the longitudinal trends of CMT or IRF improvement (P > 0.05).
Conbercept and Ranibizumab showed comparable primary outcomes and subtle divergences in exploratory secondary OCT biomarkers during the loading phase: Conbercept yielded greater DRIL reduction, whereas Ranibizumab achieved lower CMT and IRF at early time points. These preliminary findings may generate hypotheses for an OCT phenotype-driven approach to precision anti-VEGF therapy in RVO-ME.

PMID:
42656250
Bibliographic data and abstract were imported from PubMed on 27 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.